¹⁷⁷Lu-PSMA Therapy in Metastatic Castration-Resistant Prostate Cancer

The aim of this narrative review is to evaluate the current status of ¹⁷⁷Lu-PSMA (prostate specific membrane antigen) therapy for metastatic castration-resistant prostate cancer (mCRPC) in the light of the current literature. We also addressed patient preparation, therapy administration a...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Yasemin Sanli, Duygu Has Simsek, Oner Sanli, Rathan M. Subramaniam, Ayse Tuba Kendi
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	MDPI AG 2021-04-01
Edice:	Biomedicines
Témata:	CRPC <sup>177</sup>Lu-PSMA PSA prostate cancer metastasis
On-line přístup:	https://www.mdpi.com/2227-9059/9/4/430
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!